While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...
Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...
WVU medicine is conducting a trial to combat weight gain after patients stop taking GLP-1 drugs such as Ozempic. Officials ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
7h
HealthDay on MSNCan GLP-1 Meds Harm Your Eyes?Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether ...
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...
While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...
As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results